173 related articles for article (PubMed ID: 10593492)
21. Development of SHIVs with circulating, transmitted HIV-1 variants.
Sharma A; Boyd DF; Overbaugh J
J Med Primatol; 2015 Oct; 44(5):296-300. PubMed ID: 26101933
[TBL] [Abstract][Full Text] [Related]
22. The levels of DNGR-1 and its ligand-bearing cells were altered after human and simian immunodeficiency virus infection.
Yao WR; Li D; Yu L; Wang FJ; Xing H; Yang GB
Immunol Res; 2017 Aug; 65(4):869-879. PubMed ID: 28478499
[TBL] [Abstract][Full Text] [Related]
23. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
[TBL] [Abstract][Full Text] [Related]
24. HIV vaccine research and discovery in the nonhuman primates model: a unified theory in acquisition prevention and control of SIV infection.
Lynch RM; Yamamoto T; McDermott AB
Curr Opin HIV AIDS; 2013 Jul; 8(4):288-94. PubMed ID: 23666390
[TBL] [Abstract][Full Text] [Related]
25. Nonhuman primate models for HIV vaccine development.
Letvin NL
Immunodefic Rev; 1992; 3(3):247-60. PubMed ID: 1510838
[TBL] [Abstract][Full Text] [Related]
26. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
27. Surrogates of protection in repeated low-dose challenge experiments.
Long DM; Hudgens MG; Wu CD
Stat Med; 2015 May; 34(10):1747-60. PubMed ID: 25628249
[TBL] [Abstract][Full Text] [Related]
28. AIDS vaccine models: challenging challenge viruses.
Feinberg MB; Moore JP
Nat Med; 2002 Mar; 8(3):207-10. PubMed ID: 11875482
[No Abstract] [Full Text] [Related]
29. Current advances in HIV vaccine preclinical studies using Macaque models.
Liang B; Li H; Li L; Omange RW; Hai Y; Luo M
Vaccine; 2019 Jun; 37(26):3388-3399. PubMed ID: 31088747
[TBL] [Abstract][Full Text] [Related]
30. Primate models of AIDS vaccine development.
Lamb-Wharton RJ; Joag SV; Stephens EB; Narayan O
AIDS; 1997; 11 Suppl A():S121-6. PubMed ID: 9451975
[No Abstract] [Full Text] [Related]
31. Antibodies and resistance to natural HIV infection.
Nabel GJ; Sullivan NJ
N Engl J Med; 2000 Oct; 343(17):1263-5. PubMed ID: 11071680
[No Abstract] [Full Text] [Related]
32. CD8(+)T-cell-mediated control of HIV-1 and SIV infection.
Freel SA; Saunders KO; Tomaras GD
Immunol Res; 2011 Apr; 49(1-3):135-46. PubMed ID: 21170741
[TBL] [Abstract][Full Text] [Related]
33. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
34. Monkey Models and HIV Vaccine Research.
Chen Z
Adv Exp Med Biol; 2018; 1075():97-124. PubMed ID: 30030791
[TBL] [Abstract][Full Text] [Related]
35. The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies.
Van Rompay KK
AIDS Res Hum Retroviruses; 2012 Jan; 28(1):16-35. PubMed ID: 21902451
[TBL] [Abstract][Full Text] [Related]
36. Annual updated survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates.
Warren JT; Dolatshahi M
J Med Primatol; 1994; 23(2-3):184-225. PubMed ID: 7966234
[No Abstract] [Full Text] [Related]
37. An underestimated lentivirus model: what can HIV-2 research contribute to the development of an effective HIV-1 vaccine?
Hodges-Mameletzis I; De Bree GJ; Rowland-Jones SL
Expert Rev Anti Infect Ther; 2011 Feb; 9(2):195-206. PubMed ID: 21342067
[TBL] [Abstract][Full Text] [Related]
38. Towards an HIV-1 vaccine: lessons from studies in macaque models.
Hulskotte EG; Geretti AM; Osterhaus AD
Vaccine; 1998; 16(9-10):904-15. PubMed ID: 9682336
[TBL] [Abstract][Full Text] [Related]
39. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
40. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.
Zhan X; Martin LN; Slobod KS; Coleclough C; Lockey TD; Brown SA; Stambas J; Bonsignori M; Sealy RE; Blanchard JL; Hurwitz JL
Vaccine; 2005 Nov; 23(46-47):5306-20. PubMed ID: 16095768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
